Agios Pharmaceuticals (AGIO) Stock Analysis & AI Equity Report

Medical - Pharmaceuticals USD Explore free reports

Agios Pharmaceuticals (AGIO) overview

Agios Pharmaceuticals (AGIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 54.0m and operating profit of USD -472m; the year-end share price was 27.22 USD and market capitalisation was USD 1,591m. Agios Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Agios Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 1,193mFY 2025
Share price27.22 USDFY 2025 year end
RevenueUSD 54.0mFY 2025
Operating profitUSD -472mFY 2025
Net earningsUSD -413mFY 2025
Market capitalisationUSD 1,591mFY 2025 year end

About Agios Pharmaceuticals

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare disease medicines, with a foundation in hematology. Its approved medicine mitapivat is marketed as AQVESME and PYRUKYND for specified forms of thalassemia and pyruvate kinase deficiency. The company is also developing medicines for conditions including myelodysplastic syndromes, sickle cell disease, phenylketonuria and polycythemia vera.

Generate the Agios Pharmaceuticals report

Agios Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Agios Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Agios Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.